The effects of some α-adrenoceptor antagonists on the responses of the canine saphenous vein to B-HT 933, UK-14304 and methoxamine

Summary The benzoquinolizines Wy 25309, Wy 26703 and Wy 27127, previously reported as potent antagonists at presynaptic ₂-adrenoceptors were also potent antagonists of B-HT 933 in isolated saphenous veins of the dog confirming their activity at post synaptic ₂-adrenoceptors. Yohimbine was a more potent antagonist of B-HT 933 in isolated saphenous vein than were the Wy compounds or idazoxan contrasting with the reported potencies of these compounds at presynaptic sites in rat vas deferens and raising the possibility of differences between pre- and postsynaptic ₂adrenoceptors. Contractions of the saphenous vein were observed with high concentrations of idazoxan. Send offprint requests to K. F. Rhodes at the above address     

Contraction-mediating α2-adrenoceptors in the mouse vas deferens

Summary The question of the existence of postjunctional, contraction-mediating ₂-adrenoceptors, in addition to the known ₁-adrenoceptors, was studied in the mouse isolated vas deferens. Both the ₁-selective agonist phenylephrine and the ₂-selective agonist 5-bromo-6-(2imidazolin-2-ylamino)-quinoxaline (UK 14,304) caused contraction of the vas deferens. In the presence of the ₁-selective antagonist prazosin (added in order to prevent an ₁ component in the effect of high concentrations of UK 14,304), the ₂-selective antagonists yohimbine and idazoxan shifted the concentration—response curve of UK 14,304 to the right in a manner compatible with competitive antagonism and with dissociation constants K_B indicating the involvement of ₂-adrenoceptors. The maximal contraction elicited by UK 14,304 (in the presence of prazosin) was much lower than the maximal contraction elicited by phenylephrine. The effect of UK 14,304 was not changed by the P₂-purinoceptor agonist ,-methylene-ATP and was reduced by neuropeptideY, but was markedly enhanced by relatively low concentrations of phenylephrine. When the sympathetic fibres of the vas deferens were stimulated by trains of ten widely spaced (0.5 Hz) electric pulses, the tissue responded with ten separate twitches in which purinergic and adrenergic components were isolated by prazosin and suramin, respectively. Prazosin reduced the first adrenergic twitch in these trains at concentrations close to its K_B value at ₁-adrenoceptors, whereas yohimbine and idazoxan reduced the first adrenergic twitch at concentrations far lower than their K_B values at ₁-adrenoceptors. The results indicate that the smooth muscle of the mouse vas deferens possesses contraction-mediating ₂-adrenoceptors. They are activated by UK 14,304 and probably also by noradrenaline of neural origin. Responses mediated by the ₂-adrenoceptors are enhanced by simultaneous ₁-receptor activation, an interaction that may increase the contribution of the ₂-adrenoceptors to the adrenergic phase of neurogenic contractions. Send offprint requests to R. Bültmann at the above address     

H3 receptor-mediated inhibition of noradrenaline release: an investigation into the involvement of Ca2+ and K+ ions,G protein and adenylate cyclase

The effects of ₂-adrenoceptor agonists (dexmedetomidine, oxymetazoline), alone or in combination with various -adrenoceptor subtype-selective antagonists (CH-38083, idazoxan, WB4101, BRL44408, ARC-239, prazosin), on noradrenaline- and isoprenaline-induced lipolysis were investigated in human isolated abdominal subcutaneous fat cells. The rank order of potency of antagonists in preventing dexmedetomidine- and oxymetazoline-evoked suppression of isoprenaline-induced lipolysis was (pA₂-values): CH-38083 (7.69 and 7.48) idazoxan (7.5 and 7.41) > BRL 44408 (7.23 and 7.19) WB 4101 (7.13 and 7.12) > prazosin (5.18 and 5.17) > ARC-239 (4.72, 4.9). While CH-38083 and idazoxan, non-subtype selective ₂-adrenoceptor antagonists and BRL44408, a selective a_2A-adrenoceptor antagonist as well as WB4101 potentiated the lipolytic effect of noradrenaline, ARC-239, the selective _2B-adrenoceptor antagonist failed to affect it. In addition since the _2A-adrenoceptor selective agonist, oxymetazoline concentration dependently inhibited the lipolytic effect of isoprenaline, and WB4101 and BRL44408 (a_2A-adrenoceptor antagonists) antagonised the effect of oxymetazoline in a competitive manner, it is concluded that the a_2A-adrenoceptor subtype is involved in antilipolysis. In addition, functional evidence was obtained that there is an interaction between _2A- and -adrenoceptors located on the cell surface of adipocytes, through which locally released noradrenaline and/or circulating circulating adrenaline influence lipolysis.On leave from Institute of Medical Pharmacology, University of Pisa, Via Roma 55, I-5626 Pisa, Italy Correspondence to: E. S. Vizi at the above address     

Comparison of the α-adrenoceptor antagonist profiles of idazoxan (RX 781094), yohimbine,rauwolscine and corynanthine

Summary In the present studies the potency and selectivity of idazoxan (RX 781094) were compared with yohimbine and its diastereoisomers rauwolscine and corynanthine in both functional studies and radioligand binding experiments. Prejunctional ₂- and postjunctional ₁-adrenoceptor antagonist potencies were assessed by determining pA₂ values against clonidine on the stimulated rat vas deferens and noradrenaline on the anococcygeus muscle, respectively. The rank order of prejunctional ₂-adrenoceptor antagonist potency was idazoxan > yohimbine > rauwolscine corynanthine. At postjunctional ₁-adrenoceptors the rank order of antagonist potency was rauwolscine > corynanthine > yohimbine > idazoxan. The selectivity values (₂/₁) for idazoxan, yohimbine, rauwolscine and corynanthine were 245, 45, 3 and 0.03 respectively. The selectivity and potency profiles established for these antagonists in functional studies were confirmed in radioligand binding studies utilising ³H-idazoxan (₂) and ³H-prazosin (₁) in rat cerebral cortex.In pithed rats intravenously administered idazoxan, yohimbine and rauwolscine fully reversed the inhibitory effects of clonidine on electrically-induced contractions of the vas deferens; idazoxan was approximately ten times more potent than both yohimbine and rauwolscine. Corynanthine was inactive. Idazoxan and yohimbine also fully antagonised the inhibitory effects of guanabenz on electrically-induced contractions of the anococcygeus muscle; idazoxan again was more than ten times more potent than yohimbine in this model. The inhibitory effects of guanabenz were less readily antagonised by rauwolscine indicating that the selectivity of this compound is less than that of yohimbine in this tissue. Corynanthine was again inactive.Studies were also undertaken in which the effects of an extended range of antagonists were examined on contractions of the anococcygeus muscle induced either by electrical stimulation or intra-arterial phenylphrine. Selective ₁-adrenoceptor antagonists produced a parallel block of the effects of stimulation and phenylephrine indicating that the postjunctional receptor in this tissue is predominantly ₁- character. In this tissue idazoxan potentiated nerve stimulation without inhibiting phenylephrine responses; of the compounds studied only idazoxan failed to influence phenylephrine responses.Under the present experimental conditions idazoxan only produced antagonist properties at -adrenoceptors and consistently displayed improved ₂-selectivity and potency with respect to yohimbine and rauwolscine.     

Discriminative stimulus effects of the α2-adrenoceptor antagonist idazoxan

Rats were trained to discriminate a dose of the ₂-adrenoceptor antagonist idazoxan (10 mg/kg IP) from saline. The discriminative stimulus produced by idazoxan was dose related and generalised to yohimbine. However, generalisation did not occur with a variety of compounds from other pharmacological categories including the ₁-adrenoceptor agonist cirazoline, the ₂-adrenoceptor antagonist prazosin, and the ₂-adrenoceptor agonist clonidine. The idazoxan stimulus was not antagonised by either prazosin or clonidine, although it was clear that idazoxan antagonised the reductions in response rate produced by clonidine. Dose-related responding on the idazoxan-associated lever was produced by the anxiolytics buspirone and ipsapirone and by their metabolite MJ 13653 (1-PP), which has previously been shown to be an ₂-adrenoceptor antagonist. In general, however, high levels of generalisation occurred with these three compounds only at doses which substantially reduced response rates. These results demonstrate that idazoxan can give rise to a discriminative stimulus which is probably mediated through antagonism at ₂-adrenoceptors although the failure of clonidine to block the idazoxan stimulus is difficult to explain.     

The modulation of [3H]noradrenaline and [3H]serotonin release from rat brain synaptosomes is not mediated by the α2B-adrenoceptor subtype

Summary The present study aimed at relating the presynaptic ₂-adrenoceptors, known to modulate noradrenaline and serotonin release, with the recently described _2A- and _2B-adrenoceptor subtypes. The effects of the agonist oxymetazoline (selective for _2A subtype) and of three adrenoceptor antagonists (idazoxan, 1-(2-pyrimidinyl)piperazine (PmP) and prazosin, the last one known to be _2B selective) were evaluated on [³H]noradrenaline and [^H]serotonin release in superfused synaptosomes from rat brain cortex. These drugs were also tested in [³H]yohimbine binding to human platelet membranes (containing only _2A receptors) and to neonatal rat lung membranes (containing only _2B receptors).The affinity pattern of these compounds at _2A-adrenoceptors in binding studies was oxymetazoline > = idazoxan > PmP > prazosin; at _2B-adrenoceptors it was idazoxan > = prazosin > PmP = oxymetazoline. Oxymetazoline inhibited with high and similar potencies the K⁺-evoked [³H]noradrenaline and [³H]serotonin release, IC₅₀ 18 and 7 nM, respectively; in the same conditions, the IC₅₀ values of noradrenaline were 42 and 168 nM, respectively. The antagonist affinity pattern (antagonism against noradrenaline) was idazoxan > PmP > prazosin, either on [³H]serotonin release.These results indicate that presynaptic ₂ auto- or heteroreceptors do not belong to the _2B subtype and suggest that the modulation of noradrenaline and serotonin release may be mediated by the _2A-adrenoceptor subtype. Send offprint requests to M. Gobbi at the above address     

A difference in the affinity of some selective α2-adrenoceptor antagonists when compared on isolated vasa deferentia of rat and rabbit

Summary The ₂-adrenoceptor antagonist potencies of the benzoquinolizines (Wy 26 703, Wy 25 309, Wy 26 392), the benzodioxans (RX 781 094, RS 21 361), yohimbine and rauwolscine have been compared at presynaptic ₂-adrenoceptors in the isolated vasa deferentia of the rat and rabbit. Yohimbine and rauwolscine are of equal potency as antagonists in both the rat and rabbit against the agonists clonidine or UK 14 304. The benzoquinolizines and benzodioxans are very weak antagonists of clonidine or UK 14 304 at the presynaptic ₂-adrenoceptors of the rabbit vas deferens when compared to their potency at the presynaptic ₂-adrenoceptors of the rat vas deferens. This suggests that the presynaptic ₂-adrenoceptors present in the rat vasa deferentia may be different from those present in the rabbit vasa deferentia.     

Changes in platelet alpha2-adrenoceptors in human phaeochromocytoma

Summary In a 44 year-old male with a surgically proven phaeochromocytoma platelet ₂-adrenoceptor density, determined by³H-yohimbine binding, was only 50% of that in an age-matched control group, and plasma catecholamines were elevated. Two weeks after removal of the tumour, platelet ₂-adrenoceptor density and plasma catecholamines had become normal and were not significantly different from the controls. It is concluded that endogenous catecholamines may play an important role in regulation of ₂-adrenoceptor density and hence tissue sensitivity to -adrenergic stimulation in the human being.     

Possible involvement of presynaptic α1-adrenoceptors in the effects of idazoxan and prazosin on 3H-noradrenaline release from tail arteries of SHR

Summary The effects of several -adrenoceptor antagonists have been examined on tritium release elicited by electrical stimulation from isolated perfused SHR tail artery preparations prelabelled with ³H-noradrenaline (³H-NA). Phentolamine and yohimbine potently facilitated the stimulation evoked release of tritium at low frequencies of stimulation, but the ₂-adrenoceptor antagonist idazoxan was only weakly active at 1 mol/l, despite antagonising the clonidine-evoked inhibition of ³H-release at a lower concentration of 0.1 mol/l. The ₁-adrenoceptor antagonists prazosin and corynanthine also increased stimulation evoked tritium release in this preparation, suggesting the presence of prejunctional ₁-adrenoceptors. Furthermore, the ₁-adrenoceptor agonist methoxamine (3 mol/l) caused a significant inhibition of tritium-evoked release, an effect which was blocked by prazosin (10 nmol/l).When ₁-adrenoceptors were blocked in the presence of prazosin, idazoxan (0.1 mol/l) produced a significant facilitatory effect on the electrically-evoked release of ³H-transmitter. On the other hand, when ₂-adrenoceptors were blocked in the presence of yohimbine, exposure to idazoxan (0.1 mol/l) reduced significantly the stimulation-evoked release of tritium elicited by electrical stimulation.The results indicate that in the SHR tail arteries, idazoxan has a partial agonist inhibitory activity on transmitter release, which can mask the facilitatory effects due to blockade of presynaptic ₂-adrenoceptors. The inhibitory effects of idazoxan appear to involve presynaptic ₂-adrenoceptors, which when stimulated, reduce ³H-NA release in SHR tail arteries.     

Binding of aprindine and moxaprindine to human serum, α1-acid glycoprotein and serum of healthy and diseased humans

Summary A comparison was made between the binding of the anti-arrhythmic agents aprindine and moxaprindine to human serum, to human serum albumin (HSA), to ₁-acid glycoprotein (₁-AGP) and to a mixture of HSA and ₁-AGP. In serum from healthy volunteers (n=4) the binding of aprindine-HCl 5 µg/ml (13.8 µM) was 93.8% (SD±1.0), and that of moxaprindine-HCl 5 µg/ml (12.8 µM) was 94.1% (SD±1.1). Their binding to the mixture of ₁-AGP and albumin approximated their binding to serum. For ₁-AGP, the binding was similar for both compounds, whereas for HSA the binding of aprindine was more pronounced than that of moxaprindine: for both products the affinity coefficient for binding to ₁-AGP was about 100 times greater than that for binding to albumin. In serum from rheumatoid patients and from patients with renal failure a small but significant increase in binding of aprindine and moxaprindine was observed, approximately 1%. Increased and decreased binding was seen in serum from cirrhotic patients; for example, for aprindine the range in cirrhosis was 96.7%–79.8%, and the range in controls was 95.0%–92.4%. Free drug fraction and ₁-AGP concentration were inversely correlated. The results show that ₁-AGP plays an important role in the binding of aprindine and moxaprindine, and that alteration in the binding of the two compounds in disease states to a large extent can be explained by changes in serum ₁-AGP concentration.     

Influence of continuous ambulatory peritoneal dialysis on serumα 1-acid glycoprotein concentration and drug binding

Summary The influence of continuous ambulatory peritoneal dialysis (CAPD) on the concentrations of ₁-acid glycoprotein in serum and dialysate and on the serum binding of oxprenolol, propranolol and phenytoin has been studied.Before starting CAPD treatment, the serum binding of oxprenolol and propranolol was higher and that of phenytoin lower than in healthy volunteers, and the serum ₁-AGP concentration was higher. During the first days to weeks after starting CAPD, the serum ₁-AGP concentration rose with a concomitant increase in the binding of oxprenolol and propranolol. Subsequently, the ₁-AGP level and the binding of oxprenolol and propranolol decreased to the values found before starting CAPD. The binding of phenytoin showed little change. The concentration of ₁-AGP in dialysate was 2 to 5% of that in serum.     

Postjunctional α-adrenoceptors

Summary The postsynaptic -adrenoceptors in rat aorta and in pithed rat were investigated according to their sensitivity to nine -adrenergic agonists and to the selective antagonists yohimbine (₂) and prazosin (₁) and the non-selective one, phentolamine. In addition, in radioligand binding studies, the affinity and selectivity of the drugs were determined on rat cerebral cortex using [³H] yohimbine and [³H] prazosin.On rat aorta, prazosin is 1,000 times more potent than yohimbine against each -adrenoceptor agonist, whether ₁- or ₂-selective. Rat aorta probably contains only ₁-adrenoceptors.Pressor effects in pithed rats are mediated by post-junctional ₁- and ₂-adrenoceptors. The dose-response curve for -methylnorepinephrine in the presence of prazosin, using Hofstee's plots, revealed ₁- and ₂-adrenoceptors, respective proportions being 80.5 and 19.5%     

Alpha2-adrenoceptor antagonism and other pharmacological antagonist properties of some substituted benzoquinolizines and yohimbine in vitro

Summary Comparison of pA₂ values for antagonism of clonidine induced inhibition of the electrically evoked contraction of the rat isolated vas deferens ( ₁-adrenoceptors) and antagonism of contractions to methoxamine on the rat isolated anococcygeus ( ₂-adrenoceptors) showed a group of substituted benzoquinolizines (Wy 25309, 26392 and 26703) to be more potent and more selective ₂-adrenoceptor antagonists than yohimbine.The benzoquinolizines and yohimbine enhanced stimulation-evoked overflow of tritium from rabbit isolated pulmonary arteries preloaded with [³H]-noradrenaline, as expected for ₂-adrenoceptor antagonists. In contrast to the results on the rat vas deferens, yohimbine was more potent than the benzoquinolizines. At higher concentrations all the -adrenoceptor antagonists reduced the stimulation-evoked contraction of the pulmonary artery.The benzoquinolizines were competitive antagonists of 5-hydroxytryptamine on the rat isolated ileum. Wy 25309 showed only weak activity (pA₂=5.21) whereas Wy 26703 was more potent (pA₂=7.25). Yohimbine was a potent antagonist of 5-hydroxytryptamine.Wy 26703 was the only compound to have histamine antagonist effects in the guinea pig isolated ileum and to antagonise the chronotropic effect of isoprenaline on the isolated atria of the guinea pig and in both instances activity was weak (pA₂ values 5.3 and 5.5 respectively). Yohimbine reduced the spontaneous beating of the atria at 3×10^–6 M. No compound at 10^–5 M antagonised acetylcholine on the guinea pig ileum. These novel substituted benzoquinolizines should be useful experimental compounds for the study of -adrenoceptors mediated responses.     

Alpha2-adrenoceptor-mediated responses to so-called selective alpha1-adrenoceptor agonists after partial blockade of alpha1-adrenoceptors

Summary In dog saphenous vein — a tissue possessing both postsynaptic ₁- and ₂-adrenoceptors — the effects of two selective ₁-adrenoceptor agonists (phenylephrine and methoxamine) were compared with that of the selective ₂-adrenoceptor agonist, UK-14,304, before and after phenoxybenzamine. Furthermore, the influence exerted by prazosin, yohimbine and verapamil on the effects of these agonists was also studied before and after phenoxybenzamine. In the absence of phenoxybenzamine, prazosin (56 nmol/l) caused a parallel shift of the concentration-response curves of both phenylephrine and methoxamine to the right (by 0.94 and 1.1 log units, respectively) and had no effect on the concentration-response curve of UK-14,304, while 20 nmol/l yohimbine caused a marked parallel shift of the concentration-response curve of UK-14,304 to the right (by 1.18 log units) and caused only minor displacements of those of phenylephrine and methoxamine (by 0.2 and 0.33 log units, respectively). After exposure of the strips to 30 nmol/l phenoxybenzamine, prazosin (56 nmol/l) caused small shifts of the concentration-response curves of both phenylephrine (by 0.36 log units) and methoxamine (by 0.31 log units) and did not change that of UK-14,304, while yohimbine (20 nmol/l) caused pronounced parallel shifts of the concentration-response curves (to the right) of all the agonists: phenylephrine (by 1.0 log units), methoxamine (by 0.93 log units) and UK-14,304 (by 1.28 tog units). When UK-14,304 was added to the bath during a sub-maximal contraction to phenylephrine it caused a further contraction almost up to the maximum; if this procedure was repeated after phenoxybenzamine (30 nmol/1), there was no further contraction to UK-14,304.In the absence of phenoxybenzamine, verapamil (5 mol/l) caused a parallel shift of the concentration-response curve of phenylephrine (or methoxamine) to the right and a non-parallel shift (with marked depression of the maximal effect) of that of UK-14,304. However, after phenoxybenzamine (30 nmol/l), the same concentration of verapamil caused non-parallel shifts of the concentration-response curves of the three agonists to the right with about equal depression of the maximal effects. We conclude that, after removal of ₁-adrenoceptor reserve by phenoxybenzamine, the responses to selective ₁-adrenoceptor agonists are predominantly ₂-adrenoceptor-mediated. This may explain why under these conditions, the selective ₁-and ₂-adrenoceptor agonists are equally antagonized by calcium entry blockers.This work was supported by a grant from the University of Porto (Subsidio para acção de investigação no. 36/85) Send offprint requests to S. Guimarães at the above address     

Evidence in favour of a selective α1-adrenoceptor blocking action of WB 4101 in vivo

Summary The -adrenoceptor blocking potency of WB 4101 at ₁- and ₂-adrenoceptors has been investigated in pithed rats.WB 4101 was approximately 97 times more potent at antagonizing the vasopressor responses produced by the selective ₁-adrenoceptor agonist phenylephrine, than those produced by the selective ₂-adrenoceptor agonist M-7.A dose of WB 4101 (3 mg/kg) that caused extensive blockade of vascular ₁-adrenoceptors, but little or no blockade of vascular ₂-adrenoceptors, exerted no significant blockade of the presynaptic ₂-adrenoceptors in the rat heart.The results support the view that WB 4101 is a highly selective antagonist at ₁-adrenoceptors in vivo.     

Presynaptic α2A-adrenoceptors inhibit the release of endogenous dopamine in rabbit caudate nucleus slices

₂-Adrenoceptors modulating the release of dopamine were identified and characterized in slices of the head of the rabbit caudate nucleus. Release of endogenous dopamine was measured by fast cyclic voltammetry as the increase in the extracellular concentration of dopamine elicited by electrical stimulation. The electrochemical signal was identified as dopamine by means of the oxidation potential, the voltammogram and the fact that the signal was not changed by desipramine, which inhibits the high affinity uptake of noradrenaline, but was greatly increased by nomifensine, which in addition inhibits the high affinity uptake of dopamine.Stimulation by 6 pulses/100 Hz increased the extracellular concentration of dopamine by about 85 nM. The selective ₂-adrenoceptor agonist 5-bromo-6-(2-imidazolin-2-ylamino)-quinoxaline (UK 14,304) reduced this release with an EC₅₀ of 173 nM and by maximally 75%. The ₂-adrenoceptor agonists clonidine and oxymetazoline only tended to cause a decrease. Six drugs, including oxymetazoline, were tested as antagonists against UK 14,304. Their order of antagonist potency (pK_D values in brackets) was rauwolscine (8.0) > oxymetazoline (7.5) > 2-(2,6-dimethoxyphenoxyethyl)aminomethyl-1,4-benzodioxane (WB 4101; 7.3) > phentolamine (7.1) > corynanthine (5.1) prazosin (< 6). Given alone, the antagonists did not change the release of dopamine elicited by 6 pulses/100 Hz, and the same was true for the dopamine receptor antagonist sulpiride. When caudate slices were stimulated by 10 pulses/1 Hz, sulpiride increased the release of dopamine. Desipramine and rauwolscine, in contrast, again caused no change.It is concluded that dopaminergic axons in the rabbit caudate nucleus possess release-inhibiting ₂-adrenoceptors. The antagonist affinities indicate that they belong to the _2A subtype. In this, they agree with all presynaptic ₂-autoreceptors studied so far in rabbits as well as with the ₂-heteroreceptors modulating the release of serotonin in rabbit brain cortex, suggesting that at least the majority of presynaptic ₂-adrenoceptors in the rabbit are _2A. The agonist sensitivity of the caudate presynaptic ₂-adrenoceptors is low in comparison with cerebrocortical presynaptic ₂-autoreceptors, possibly due to absence of a receptor reserve. Correspondence to: N. Limberger at the above address     

Exploring the pharmacology of the pro-convulsant effects of α2-adrenoceptor antagonists in mice

The effects of selective and specific ₂-adrenoceptor antagonists on electroshock seizure threshold in mice were investigated. Idazoxan, at low doses, efaroxan, RX811059 and RX821002 significantly lowered seizure threshold. The ₁-agonist St 587 and the -agonist isoprenaline were also pro-convulsant. On the other hand the ₂-agonists clonidine and UK 14,304 produced small increases in seizure threshold. Anticonvulsant effects were also produced by low doses of the noradrenaline uptake inhibitor desipramine. This compound increases levels of noradrenaline in the synaptic cleft which could subsequently act at post-synaptic ₂-adrenoceptors. The pro-convulsant action of ₂-adrenoceptor antagonists could be explained in terms of two mechanisms: a) blockade of endogenous noradrenaline which may normally exert a tonic anti-convulsant influence on seizure threshold, through post-synaptic ₂-receptors and/or b) increased activation of ₁- and -adrenoceptors by elevated synaptic noradrenaline levels following blockade of pre-synaptic ₂-adrenoceptors. Of the ₂-antagonists tested, idazoxan was unusual in that high doses were not pro-convulsant; this difference may be explained by ₁-adrenoceptor mediated actions or be related to its recently described affinity at a non-adrenoceptor site — a function for which is currently unknown.     

Release-inhibiting α2-adrenoceptors at serotonergic axons in rat and rabbit brain cortex: evidence for pharmacological identity with α2-autoreceptors

The pharmacological properties of the presynaptic ₂-adrenoceptors modulating the release of serotonin in rat and rabbit brain cortex (₂-heteroreceptors) were compared with the properties of presynaptic ₂-autoreceptors in the same brain area. Brain cortex slices were preincubated with [³H]-serotonin or [³H]-noradrenaline and then superfused and stimulated by brief high-frequency pulse trains.The ₂-adrenoceptor agonist bromoxidine reduced the electrically evoked overflow of tritium in experiments with both [³H]-noradrenaline and [³H]-serotonin and in brain slices from either species. The antagonists phentolamine, idazoxan, (+)-mianserin, rauwolscine, 5-chloro-4(1-butyl-1,2,5,6-tetrahydropyridin-3-yl)-thiazole-2-amine (ORG 20350), 2-(2,6-dimethoxyphenoxyethyl)aminomethyl-1,4-benzodioxane (WB 4101), (–)-mianserin and corynanthine caused parallel shifts of the concentration-inhibition curves of bromoxidine to the right. Negative logarithms of antagonist dissociation constants pK_d were calculated from the shifts. In the rat, the ₂-autoreceptor pK_d value of each single antagonist was similar to its ₂-heteroreceptor pK_d value, maximal difference 0.4, giving a close correlation, r = 0.97 (P<0.001). In the rabbit equally, the ₂-autoreceptor pK_d value of each single antagonist was similar to its ₂-heteroreceptor pK_d value, maximal difference 0.4, again yielding a close correlation, r = 0.96 (P < 0.001). However, antagonist pK_d values at rat ₂-autoreceptors differed from those at rabbit ₂-autoreceptors, r = 0.70 (P > 0.05), and antagonist pK_d values at rat ₂-heteroreceptors differed from those at rabbit ₂-heteroreceptors, r = 0.64 (P > 0.05). Comparison with radioligand binding experiments from the literature indicated that, in the rat, both auto- and heteroreceptors conformed best to the _2D subtype (r 0.97, P < 0.01 for pK_d correlation with binding sites in rat submaxillary gland) whereas, in the rabbit, they conformed best to the _2A subtype (r 0.93, P < 0.01 for pK_d correlation with binding sites in HT29 cells).It is concluded that, in both the rat and the rabbit, the ₂-adrenoceptors modulating the release of serotonin are pharmacologically identical with the presynaptic ₂-autoreceptors. However, rat ₂-autoreceptors and -heteroreceptors differ pharmacologically from rabbit ₂-autoreceptors and -heteroreceptors. Presynaptic ₂-auto-as well as -heteroreceptors are _2D in the rat and _2A in the rabbit. Correspondence to: N. Limberger at the above address     

Antagonists that differentiate between α2A- and α2D-adrenoceptors

Four antagonists were examined for their ability to differentiate _2A from the orthologous _2Dadrenoceptors. The antagonists were (2S,12bS) 1, 3-di-methylspiro(1, 3, 4, 5, 6, 6, 7,12b-octahydro-2H-benzo[b]furo[2,3-a]quinolizine)-2,4-pyrimidin-2-one (MK 912), 2-[2-(methoxy-1, 4-benzodioxanyl)imidazoline (RX 821002), efaroxan and benoxathian. The ₂-autoreceptors in rabbit brain cortex were chosen as _2A- and the a₂-autoreceptors in guinea-pig brain cortex as _2D-adrenoceptors. Slices of the brain cortex were preincubated with ³H-noradrenaline and then superfused and stimulated electrically by brief pulse trains (4 pulses, 100 Hz) that led to little, if any, ₂-autoinhibition. 5-Bromo-6-(2-imidazolin-2-ylamino)quinoxaline (UK 14,304) was used as an ₂-adrenoceptor agonist.UK 14, 304 decreased the stimulation-evoked overflow of tritium. The antagonists shifted the concentration-inhibition curve of UK 14, 304 to the right in an apparently competitive manner. Dissociation constants of the antagonists were calculated from the shifts. MK 912, RX 821002 and efaroxan had markedly higher affinity for (guinea-pig) _2D-adrenoceptors (pK _d values 10.0, 9.7 and 9.1, respectively) than for (rabbit) _2A-adrenoceptors (pK _d 8.9, 8.2 and 7.6, respectively). Benoxathian had higher affinity for _2A- (pK _d 7.4) than for _2D-adrenoceptors (pK _d 6.9). Ratios calculated from the K _d values of the four compounds differentiated between _2A and _2D up to 100 fold. It is concluded that MK 912, RX 821002, efaroxan and benoxathian are antagonists with high power to differentiate _2A- from _2D-adrenoceptors.     

Subclassification of presynaptic α2-adrenoceptors: α2D-autoreceptors and α2D-adrenoceptors modulating release of acetylcholine in guinea-pig ileum

The study was designed to classify in terms of _2A, _2B, _2C and _2D the presynaptic ₂-autoreceptors, as well as the ₂-receptors modulating the release of acetylcholine, in the myenteric plexus-longitudinal muscle (MPLM) preparation of the guinea-pig ileum. A set of antagonists was chosen that was able to discriminate between the four subtypes. Small pieces of the MPLM preparation were preincubated with ³H-noradrenaline or ³H-choline and then superfused and stimulated electrically.The stimulation periods used (3H-noradrenaline: 3 trains of 20 pulses, 50 Hz, train interval 60 s; ³H-choline: single trains of 30 pulses, 0.2 Hz) did not lead to ₂-autoinhibition or inhibition of ³H-acetylcholine release by endogenous noradrenaline. The ₂-selective agonist 5-bromo6-(2-imidazolin-2-ylamino)-quinoxaline (UK 14,304) reduced the evoked overflow of tritium in both ³H-noradrenaline and ³H-choline experiments. Most (³H-noradrenaline) or all (³H-choline) of the 10 antagonists shifted the concentration-inhibition curves of UK 14,304 to the right. pK_d values of the antagonists were calculated from the shifts. pK_d values from ³H-noradrenaline experiments correlated with pK_d values from ³H-choline experiments (r = 0.981).It is concluded that ₂-autoreceptors and ₂-heteroreceptors modulating the release of acetylcholine in the MPLM preparation are of the same subtype. Comparison with antagonist affinities for prototypic native ₂ binding sites, binding sites in cells transfected with ₂ subtype genes, and previously classified presynaptic ₂-adrenoceptors — all taken from the literature — indicates that both are _2D. The results are consonant with the hypothesis that at least the majority of ₂-autoreceptors belong to the _2A/D branch of the ₂-adrenoceptor tree, across mammalian or at least across rodent and lagomorph species. The same may hold true for ₂-adrenoceptors on non-noradrenergic neurones.